WP
ENGN icon

Woodline Partners’s enGene Therapeutics ENGN Stock Holding History

Woodline Partners’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7M Hold
250,000
– – 0.01% 822
2025
Q4 		$2.26M Buy
+250,000
New +$2M 0.01% 756

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Woodline Partners's ENGN Position: Q1 2026 in Review

Woodline Partners held its enGene Therapeutics (ENGN) position steady in Q1 2026 at 250,000 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #822.

Woodline Partners first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.26M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Woodline Partners held 250,000 shares of enGene Therapeutics worth $1.7M as of Q1 2026.
  • Woodline Partners left its enGene Therapeutics share count unchanged in Q1 2026.
  • enGene Therapeutics made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #822 holding.
  • Woodline Partners first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Woodline Partners's enGene Therapeutics position peaked at $2.26M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.